A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy
CC-90011-SCLC-001
Phase 1 other active
Quick answer
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy for extensive stage small cell lung cancer is a Phase 1 program (other) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- extensive stage small cell lung cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active